University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Remplir Bio Inc.

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

ImmunologyOncology

Funding Stage

Seed

Founders

Greg Delgoffe

Remplir Bio is developing cancer immunotherapies grounded in immunometabolism—the study of how cellular metabolism shapes immune function. Cofounded in 2022 by University of Pittsburgh immunologist Greg Delgoffe, the company is translating this research into a preclinical therapeutic platform. [1] [2]

A $7 million seed round, reported by Pitt in 2024, supports the company’s effort to turn academic discoveries into new approaches to cancer treatment. [1]

Discover More with AI